Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

YMAT vs ABEO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABEO Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

ABEO Overall Winner 6-Pillar Tally: YMAT 0 – 5 ABEO (1 Tie) Matrix Metrics: YMAT 3 – 7 ABEO

As of Nov 16, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over J-Star Holding Co., Ltd. (YMAT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). YMAT carries a Unified Composite Score of 57.8/100 (HOLD) at $0.89 (N/M Forward P/E, -372.2% operating margin), whereas ABEO carries 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin).

  • Composite vs. Pillar Nuance: While YMAT currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ABEO 44.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. -372.2% operating margin) and revenue trajectory (+2745.0% vs. -36.1% YoY).
  • Technical & Structure Timing Caution: YMAT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About YMAT vs ABEO
YMAT NASDAQ
J-Star Holding Co., Ltd. Ordinary Shares
Sporting & Athletic Goods, Nec
$0.89
-16.02% 1D
Market Cap $4.8M
TTM Revenue $6.1M
Forward P/E N/M
Beta / 30D Vol 5.73β · 218% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 75.0 Fund 59.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.2%), weak momentum, RSI 40
RSI-14: 39.8 · SMA20: $1.58 · SMA50: $1.59
ABEO NASDAQ Head-to-Head Winner
Abeona Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.60
+7.44% 1D
Market Cap $149.2M
TTM Revenue $39M
Forward P/E 18.7x
Beta / 30D Vol 0.60β · 149% Vol
Unified Composite Score
44.9 / 100 HOLD
Tech 60.0 Fund 52.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.6%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $3.77 · SMA50: $4.63

6-Pillar Scorecard Institutional Category Breakdown (YMAT 0 – 5 ABEO)

Columns: Metric · YMAT · ABEO
1. Valuation Multiples ABEO
Forward P/E N/M 18.7x
Trailing P/E N/M 18.7x
PEG Ratio N/M N/M
EV / Revenue 0.8x 2.6x
2. Growth & Scale ABEO
Revenue Growth (YoY) -36.1% +2745.0%
Earnings Growth (YoY) -56.4% +0.0%
TTM Revenue (USD) $6.1M $39M
Market Cap $4.8M $149.2M
3. Profitability & Quality ABEO
Gross Margin 57.0% -3.5%
Operating Margin -372.2% -186.1%
Net Profit Margin 0.0% -160.3%
Return on Equity (ROE) -275.9% -42.1%
4. Balance Sheet & Cash Flow ABEO
Cash Generation (TTM) -$22M EBITDA -$66M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.64 Book/Sh · -275.9% ROE $50M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABEO
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) 165.8% (27th %ile)
Put/Call OI Skew N/A 0.19x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: YMAT (3) vs ABEO (7)
Institutional Metric YMAT ABEO Criterion Row Edge
Market Capitalization
Scale
$4.8M $149.2M Larger Scale ABEO
Trailing P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Forward P/E Ratio
Valuation
N/M 18.7x Lower Multiple ABEO
Revenue Growth (YoY)
Growth
-36.1% +2745.0% Higher Growth ABEO
Operating Margin (TTM)
Profitability
-372.2% -186.1% Higher Margin ABEO
Net Profit Margin
Profitability
0.0% -160.3% Higher Margin YMAT
Return on Equity (ROE)
Capital Efficiency
-275.9% -42.1% Higher ROE ABEO
52-Week Range Position
Momentum
15% ($0–$4) 9% ($2–$8) Stronger Trend YMAT
Beta / 30D Volatility
Risk Regime
5.73β · 218% Vol 0.60β · 149% Vol Lower Realized Risk ABEO
Unified Institutional Score
Composite Signal
57.8 / 100 (HOLD) 44.9 / 100 (HOLD) Higher Composite YMAT
Trailing 12M Revenue (USD)
Operating Scale
$6.1M $39M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.0% -3.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M EBITDA ($0.64 Book/Sh · -275.9% ROE) -$66M ($50M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon YMAT +9.26 pp
YMAT: -32.05% · ABEO: -41.31%
3M Horizon YMAT +4.4 pp
YMAT: -53.39% · ABEO: -57.79%
6M Horizon YMAT +14.71 pp
YMAT: -36.87% · ABEO: -51.58%
1Y Horizon YMAT +49.72 pp
YMAT: +7.12% · ABEO: -42.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on YMAT vs ABEO. Trailing 12-month operating profitability (YMAT -372.2% vs ABEO -186.1%) and valuation multiples (YMAT N/M vs ABEO 18.7x Forward P/E) are benchmarked directly in Pillar 4 below.

YMAT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.1M
Gross Margin57.0%
Op. Margin-372.2%
ROE / Fwd P/E-275.9% · N/M
ABEO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$39M
Gross Margin-3.5%
Op. Margin-186.1%
ROE / Fwd P/E-42.1% · 18.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
YMAT BREAKDOWN
83d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact YMAT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABEO BREAKDOWN
67d in phase · OBV DISTRIBUTION
Current IV 165.8%
IV Percentile 27th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ABEO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
YMAT Moat Profile Cyclical / Execution-Driven Positioning
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $4.8M market capitalization and -372.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABEO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $149.2M market capitalization and -186.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ YMAT vs ABEO Key Questions & Quantitative Answers

As of Nov 16, 2026, Abeona Therapeutics Inc. (ABEO) is the stronger overall head-to-head candidate over J-Star Holding Co., Ltd. (YMAT) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). YMAT carries a Unified Composite Score of 57.8/100 (HOLD) at $0.89 (N/M Forward P/E, -372.2% operating margin), whereas ABEO carries 44.9/100 (HOLD) at $2.60 (18.7x Forward P/E, -186.1% operating margin). Composite vs. Pillar Nuance: While YMAT currently prints a higher short-term Unified Composite Score (57.8/100 HOLD vs. ABEO 44.9/100 HOLD), ABEO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-186.1% vs. -372.2% operating margin) and revenue trajectory (+2745.0% vs. -36.1% YoY). Technical & Structure Timing Caution: YMAT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.8); meanwhile ABEO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABEO leads the Growth & Scale pillar: YMAT posts -36.1% YoY revenue growth and -56.4% YoY earnings growth on $6.1M TTM revenue (57.0% gross margin, -372.2% operating margin), compared with ABEO at +2745.0% YoY revenue growth and +0.0% YoY earnings growth on $39M TTM revenue (-3.5% gross margin, -186.1% operating margin). On trailing 12-month operating scale, YMAT generates $6.1M in USD-normalized revenue versus $39M for ABEO. In operating R&D and SG&A reinvestment, YMAT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABEO.

ABEO screens cheaper on headline valuation multiples. YMAT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas ABEO trades at 18.7x Forward P/E, 18.7x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against YMAT (-275.9% ROE) versus ABEO (-42.1% ROE) capital efficiency.

In options market volatility and institutional positioning, YMAT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (5.73β · 218% Vol realized risk). By comparison, ABEO carries 165.8% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.60β · 149% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.